In this 12-week pilot study, 35 adult PSC patients were randomized into one of 4 groups: 1. 125 mg oral vancomycin 4x/day 2. 250 mg oral vancomycin 4x/day 3. 250 mg metronizadole 3x/day 4. 500 mg metronizadole 3x/day One goal of this study was to investigate the safety and efficacy of these drugs. Another goal […]
Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
This case study reports on a 15 year old girl with PSC and ulcerative colitis. After taking oral vancomycin, the girl achieved normalization of her liver numbers and bile ducts, resolution of UC symptoms, and colonic mucosal healing. The investigators believe the vancomycin may be acting both as an antibiotic (by altering the intestinal microbiome) […]
Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease
This paper reviews the results of five studies that investigated the use of antibiotics (vancomycin, metronidazole, rifaximin, and minocycline) in 124 PSC patients. Specifically, this paper analyzes the impacts of the antibiotics on the following biomarkers: Mayo PSC Risk Score (MRS), ALP, total serum bilirubin, and adverse events.
Oral Vancomycin as a Therapeutic Option for PSC: Presented by Dr. Yinka Davies
In this recording from the PSC Partners’ conference in 2018, Dr. Yinka Davies shares the promising research about vancomycin for PSC. She shares incredible case studies and discusses optimal vancomycin dosing regimens and the importance of brand and much more. Since vancomycin is not yet FDA-approved for PSC, Dr. James Tabibian had to discuss the […]
Review Article: The Evidence that Vancomycin is a Therapeutic Option for Primary Sclerosing Cholangitis
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Id eu nisl nunc mi. Sed nisi lacus sed viverra tellus in hac habitasse platea. Quam elementum pulvinar etiam non quam lacus suspendisse faucibus. Eleifend donec pretium vulputate sapien nec.